Vuoristo MS - Search Results

1

Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.

Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. Vihinen PP, et al. Among authors: vuoristo ms. Acta Oncol. 2007;46(5):678-84. doi: 10.1080/02841860600965020. Acta Oncol. 2007. PMID: 17562445

2

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.

Vuoristo M, Jantunen I, Pyrhönen S, Muhonen T, Kellokumpu-Lehtinen P. Vuoristo M, et al. Eur J Cancer. 1994;30A(4):530-2. doi: 10.1016/0959-8049(94)90433-2. Eur J Cancer. 1994. PMID: 8018415 Clinical Trial.

3

The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.

Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E. Vuoristo MS, et al. Melanoma Res. 2000 Jun;10(3):237-41. Melanoma Res. 2000. PMID: 10890377 Clinical Trial.

4

Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.

Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Laine S. Vuoristo MS, et al. Acta Oncol. 2000;39(7):877-9. doi: 10.1080/028418600750063659. Acta Oncol. 2000. PMID: 11145448

5

Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.

Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Eur J Cancer. 2001 Sep;37(13):1629-34. doi: 10.1016/s0959-8049(01)00192-7. Eur J Cancer. 2001. PMID: 11527688

6

High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.

Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. Nikkola J, et al. Among authors: vuoristo ms. Clin Cancer Res. 2005 Jul 15;11(14):5158-66. doi: 10.1158/1078-0432.CCR-04-2478. Clin Cancer Res. 2005. PMID: 16033831

7

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.

Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Melanoma Res. 2005 Aug;15(4):291-6. doi: 10.1097/00008390-200508000-00010. Melanoma Res. 2005. PMID: 16034308 Clinical Trial.

8

The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma.

Vuoristo MS. Vuoristo MS. Cancer Genet Cytogenet. 2007 Jul 1;176(1):54-7. doi: 10.1016/j.cancergencyto.2007.03.002. Cancer Genet Cytogenet. 2007. PMID: 17574964

9

Serum angiogenin levels predict treatment response in patients with stage IV melanoma.

Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjänen KJ, Hahka-Kemppinen M, Kellokumpu-Lehtinen PL, Pyrhönen SO. Vihinen P, et al. Among authors: vuoristo ms. Clin Exp Metastasis. 2007;24(7):567-74. doi: 10.1007/s10585-007-9093-7. Epub 2007 Aug 29. Clin Exp Metastasis. 2007. PMID: 17762972

10

Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.

Vuoristo MS, Vihinen P, Skyttä T, Tyynelä K, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Anticancer Res. 2009 May;29(5):1755-9. Anticancer Res. 2009. PMID: 19443399 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters